1. Agosti R, Yasargil G, Egli M, Wieser HG, Wiestler OD (1990) Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res 6(2):166–170
2. Andreazza AC, Kauer-Sant’Anna M, Frey BN, Stertz L, Zanotto C, Ribeiro L, Giasson K, Valvassori SS, Réus GZ, Salvador M, Quevedo J, Gonçalves CA, Kapczinski F (2008) Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 33(6):516–524
3. Bolton JB, Rimmer E, Williams J, Richens A (1989) The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br J Clin Pharmacol 27(Suppl. 1):35S–42S
4. Bouwman BM, van Lier H, Nitert HE, Drinkenburg WH, Coenen AM, van Rijn CM (2005) The relationship between hippocampal EEG theta activity and locomotor behaviour in freely moving rats: effects of vigabatrin. Brain Res Bull 64(6):505–509
5. Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Mora GN, Osculati F, Berto E, Marconi P, Marzola A, Fabene PF, Simonato M (2010) Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation 7-81:1–6